Crisaborole
- Generic Name
- Crisaborole
- Brand Names
- Eucrisa
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10BNO3
- CAS Number
- 906673-24-3
- Unique Ingredient Identifier
- Q2R47HGR7P
- Background
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.
- Indication
Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
- Associated Conditions
- Mild Atopic dermatitis, Moderate Atopic dermatitis
Innovative Therapies for Schizophrenia, Atopic Dermatitis, Hepatitis B, and SLE Highlighted at CIIE
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.